4BIO Capital Portfolio Company Carisma to Collaborate with Moderna to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology Press Release 4BIO Capital Portfolio Company Carisma to Collaborate with Moderna to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology Collaboration will combine...

4BIO Capital Joins Investor Syndicate in CARISMA Therapeutics’ Second Closing of $59 Million Series B Round Press Release 4BIO Capital Joins Investor Syndicate in CARISMA Therapeutics’ Second Closing of $59 Million Series B Round 1 March 2021 LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”),...